

## High 18F-FDG Uptake in Benign Pathologies: A Challenge in Oncological PET/CT Imaging

Sevin Ayaz

Department of Medical Imaging Techniques, Toros University, Vocational School; Department of Nuclear Medicine, Ministry of Health, Mersin City Hospital, Mersin, Turkey

### To the editor,

Since 18F-FDG accumulation can also be seen in benign pathologies (1), it may be challenging to differentiate them from malignant tumours. For instance, in daily oncological PET/CT practice, increased FDG uptake can co-incidentally be detected in tuberculous lymph nodes, fungal infections of the liver, Nocardia abscess of the neck, intracranial and intraabdominal bacterial abscesses, bone infections, sarcoidosis, pneumoconioses, amyloidosis, autoimmune diseases of the thyroid, thymic hyperplasia, gastritis, esophagitis, acute cholangitis and cholecystitis, pericarditis, thrombus in superior vena cava, diverticulum of the urinary bladder, Paget's disease, bone marrow of anemic patients due to hyperplasia, and inflammatory changes within atheromatous plaques of the aorta and other large arteries; besides benign tumours such as pleomorphic adenoma of the parotid gland, uterine fibroids, adenoma of the thyroid, fibrous mesothelioma, colonic polyps, hypophyseal adenoma, surrenal adenoma, fibrous dysplasia, neurofibroma, enchondroma, aneurysmal

bone cyst, giant cell tumour of bone, and cystadenoma in the ovary (2–4). To make the diagnosis more complicated in oncology patients, inflammatory changes after chemotherapy, postoperative scars during healing process such as abdominal fibrosis, sternal uptake after coronary bypass, recent laminectomies, hematoma after excisional biopsies, ostomies, tube or catheter insertions and post-radiation changes (radiation pneumonitis etc.) can also cause 18F-FDG accumulation (2). In patients who would undergo oncological PET/CT imaging, 18F-FDG uptake can be seen in co-incidental pancreatitis (5). In children, bone lesions including tumours like osteoid osteoma, chondroblastoma, nonossifying fibroma, Langerhans cell histiocytosis, traumas such as bone fractures, and infectious diseases like osteomyelitis or prosthetic joint infection can present with increased 18F-FDG uptake. Also regarding the pediatric patients, focally increased 18F-FDG uptake can be demonstrated in many other inflammatory and/or infectious pathologies including abscesses, inflammatory bowel diseases, granulomatous

**Corresponding Author:** Sevin Ayaz. Medical Imaging Techniques Department, Toros University, Vocational School; Department of Nuclear Medicine, Ministry of Health, Mersin City Hospital, Mersin, Turkey

**E-mail:** sevinayaz@yahoo.com

**Received:** Jan 24, 2017

**Accepted:** May 29, 2017

**Published:** Sep 29, 2017

*This is an Open Access article distributed under the terms of Creative Commons Attribution Non-Commercial License which permits unrestricted non-commercial use, distribution, and reproduction in any area, original work is properly cited.*



The Ulutas Medical Journal © 2017

diseases/infections, fungal infections (aspergillosis etc.), pneumonia, sinusitis and injection site granulomas after subcutaneous (i.e. heparin) or intramuscular drug administrations (6).

Though  $^{18}\text{F}$ -FDG uptake due to benign pathologies is usually less than that of the malignant tumours, some overlap can occur between these two distinct entities (2). In order to differentiate benign FDG uptake from malignant, the image interpreter should get a detailed patient history (surgical and clinical history, previous and recent therapies, history of trauma etc.) and evaluate all the previously obtained radiological and scintigraphic images of the patient (1,2). In case of a need, laboratory tests and/or other imaging methods such as ultrasonography and MRI should be performed, in accordance with other disciplines. Stability of these lesions on follow-up scans is an important clue for benignity (3).

## Reference

1. Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. *Eur J Nucl Med Mol Imaging* 2015;42:328–54.
2. Abouzi MM, Crawford ES, Nabi HA.  $^{18}\text{F}$ -FDG imaging: pitfalls and artifacts. *J Nucl Med Technol* 2005;33:145–55.
3. Carter KR, Kotlyarov E. Common causes of false positive  $^{18}\text{F}$  FDG PET/CT scans in oncology. *Braz Arch Biol Technol* 2007;50:29–35.
4. Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, et al. Procedure guideline for tumor imaging with  $^{18}\text{F}$ -FDG PET/CT 1.0. *J Nucl Med* 2006;47: 885–95.
5. Sahani DV, Bonaffini PA, Catalano OA, Guimaraes AR, Blake MA. State-of-the-art PET/CT of the pancreas: current role and emerging indications. *Radiographics* 2012;32: 1133–58.
6. Shamma A, Lim R, Charron M. Pediatric FDG PET/CT: physiologic uptake, normal variants, and benign conditions. *Radiographics* 2009;29:1467–86.

### How to cite?

Ayaz S. High  $^{18}\text{F}$ -FDG Uptake in Benign Pathologies: A Challenge in Oncological PET/CT Imaging. *Ulutas Med J*. 2017; 3(3):57-58.

Doi: 10.5455/umj.20170312084153

To submit your manuscript, please click on <https://www.ulutasmedicaljournal.com>